Cellectar Biosciences (CLRB) announced a broad expansion of its global intellectual property estate, including newly issued patents across Europe, Asia-Pacific, the Middle East, and the Americas. These additions strengthen the company’s protection around iopofosine I 131, its proprietary radiotherapeutic, as well as its broader portfolio, including CLR 125, the company’s Auger-emitting radiopharmaceutical in development as a treatment for triple negative breast cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB: